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Summary
Objectives: The objective of this study was to evaluate the Candida species and the change over
time in the organisms causing candidemia at Saudi Aramco Medical Services Organization in Saudi
Arabia. We also describe the risk factors associated with mortality.
Methods: This was a retrospective study of candidemia over nine years (1996—2004).
Results: A total of 98 distinct episodes of candidemia were identified over the study period. The
annual incidence of candidemia ranged between 0.2 and 0.76 cases/1000 hospital discharges with
an incidence per 10 000 patient-days per year of 0.45 to 1.6. The most frequent Candida species
were Candida albicans (53%), Candida tropicalis (19%), Candida parapsilosis (16%), and Candida
glabrata (7%). In relation to predisposing factors, 83% of candidemia occurred in patients with
central venous catheters and 96% had received broad-spectrum antibiotics. Other predisposing
factors included complicated abdominal surgeries (22%), total parenteral nutrition (52%),
neutropenia (9%), acute renal failure (24%), malignancy (26%) and burns (15%). However, prior
fluconazole use was low (8%). The overall crude mortality rate was 43% for all candidemia.
Logistic regression analysis identified two independent determinants of death, C. albicans (OR
5.91, 95% CI 1.50, 23.24, p = 0.01) and acute renal failure (OR 5.15, 95% CI 1.18, 22.55, p = 0.03).
Conclusion: The study showed that the rate of candidemia was low in our hospital and that C.
albicans was the major species followed by C. tropicalis and C. parapsilosis. Future studies are
needed to evaluate the antifungal susceptibility pattern in our hospital.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.* Tel.: +966 3 877 3524; fax: +966 3 877 3790.
E-mail address: jaffar.tawfiq@aramco.com.
1201-9712/$32.00 # 2006 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2006.03.003Introduction
Candidemia is the fourth most common cause of blood stream
infection in the USA and is a cause of significant morbidity and
mortality.1,2 Candidemia carries a high mortality rate of 40%Published by Elsevier Ltd. All rights reserved.
240 J.A. Al-Tawfiqand a prolonged hospitalization.3 Certain patients are at high
risk of developing candidemia especially those receiving
broad-spectrum antibiotics, chemotherapy, or steroids. In
addition, the presence of central venous catheters (CVC),
administration of total parenteral nutrition (TPN), compli-
cated abdominal surgery, malignancy, neutropenia, and
acute renal failure (ARF) are additional risk factors.4,5
Historically, Candida albicans accounts for 50—70% of all
episodes of candidemia.6—8 The prevalence of non-C. albi-
cans is increasing in many centers.9—11 Moreover, the fre-
quency of C. albicans and non-C. albicans fungemia shows a
wide variation among different institutes.12—14 Few studies
have addressed the epidemiology of candidemia in Saudi
Arabia and have shown differences in the Candida species
causing fungemia in different hospitals.9,10,14—16 In this study,
a nine-year retrospective analysis was conducted to evaluate
the Candida species and the change over time in the species
causing fungemia at Saudi Aramco Medical Services Organi-
zation (SAMSO) in Saudi Arabia. In addition, we compared C.
albicans and non-C. albicans in relation to the predisposing
factors and the outcome.
Materials and methods
SAMSO provides medical care for Saudi Aramco employees
and their dependents: spouses, children, and parents.
Approximately 370 000 individuals are eligible for medical
care at SAMSO. The main hospital, Dhahran Health Center
(DHC), was initially constructed in 1944 with a capacity of 80
beds. Over the years, DHC has grown into a state of the art
380-bed referral institution, in addition to several satellite
clinics and smaller hospitals. SAMSO has five intensive care
units (cardiac, medical, surgical, pediatric, and neonatal).
Admissions to the hospital cover a whole range of patients
and include general ward admissions, intensive care, and
patients receiving chemotherapy for hematological and solid
organ malignancy. However, SAMSO does not have solid organ
or bone marrow transplant services. On average there are a
total of 36 426 admissions annually with the total number of
patient days being 193 725 annually (average length of stay
5.3 days). Of the total admissions, 4940 annual admissions
are to the intensive care units with a total of 42 956 patient
days (average length of stay 8.7 days).Table 1 Distribution of Candida spp causing fungemia over the s
Year C. albicans C. glabrata C. parapsilosis C. tr
1996 7 3
1997 6 1
1998 4 2 2
1999 4 2 3 4
2000 7 4 2
2001 10 4 4
2002 2 1 2
2003 11 2 2 2
2004 1 2
Total 52 7 16 19
a Others include: C. lusitaniae, C. krusei, and C. guilliermondii.All positive blood cultures for Candida species were iden-
tified from the microbiology and epidemiology records from
January 1996 to December 2004. Only the first episode of
candidemia per patient was included in the analysis.
A minimum of 3 mL of blood was collected aseptically by
skin venipuncture or from an indwelling catheter. The blood
was inoculated into a BACTECTM aerobic vial (Becton Dick-
inson). All positive cultures were manually sampled and
inoculated on Sabouraud glucose agar (SGA) and incubated
at 30 8C. An aliquot was Gram-stained for preliminary iden-
tification of the microorganism. C. albicans was identified
initially based on germ tube formation and subsequent yeast
species were identified using the Vitek automated system
(bioMerieux, France). Antifungal susceptibility was not done
at our laboratory. In addition, the study did not account for C.
dubliniensis.
Candidemia was defined as a positive blood culture for
Candida spp and the presence of signs and symptoms of
sepsis. For the identified cases, we collected the demo-
graphic data, underlying disease, and the presence of risk
factors (neutropenia, presence and removal of CVC, TPN,
complicated abdominal surgery, ARF, colonization with Can-
dida, and prior use of antimicrobial and antifungal agents).
We also recorded the antifungal therapy, duration of hospi-
talization prior to the development of candidemia, and the
outcome of the patient. Early mortality was defined as death
within seven days and late mortality as death between seven
and 30 days.17
Statistical analyses were performed using the statistical
package for the social sciences (SPSS version 10.0).
Mean  SD was determined for quantitative data and fre-
quency was calculated for categorical variables. The propor-
tion test was adopted to examine the significant difference
between proportions and a p-value of <0.05 was considered
significant. Logistic regression analyses were conducted to
determine the potential risk factors and death among
patients with candidemia and the risk factors associated with
the development of C. albicans among all patients.
Results
During the study period, from January 1996 to December
2004, a total of 98 distinct episodes of candidemia weretudy period by year of isolation
opicalis Others a Total Rate/1000
discharges
Rate/10 000
patient-days
1 11 0.45 1
7 0.28 0.64
8 0.32 0.72
13 0.53 1.2
1 14 0.59 1.2
18 0.76 1.6
5 0.2 0.45
17 0.7 1.5
2 5 0.22 0.46
4 98 — —
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Table 2 Demographic and clinical features of patients with
candidemia
Characteristic No. (%) of patients
Male:female (ratio) 40/58 (41:59)
Prematurity 11/91 (12)
Age >60 years 37/98 (38)
Neutropenia 8/91 (9)
Acute renal failure 21/88 (24)
Complicated abdominal surgery 20/92 (22)
Presence of CVC 74/89 (83)
Total parenteral nutrition 46/89 (52)
Colonization with Candida spp 44/91 (48)
Burns 15/98 (15)
Malignancy 25/98 (26)
Prior antibiotic use 84/87 (96)
Prior antifungal use 7/84 (8)
Initial therapy (n = 78)
Fluconazole 47 (60)
Amphotericin B 28 (36)
Itraconazole 2 (2.6)
Fluconazole and amphotericin B 1 (1.4)
Death 42/98 (43)
CVC, central venous catheter. Denominators are the number of
patients for whom information on that characteristic was avail-
able.identified. All cases were healthcare-associated candidemia.
The annual incidence of candidemia ranged from 0.2 to 0.76
(median 0.45) cases/1000 hospital discharges. The incidence
per 10 000 patient-days per year ranged from 0.45 to 1.6
(median of 1.0). Of the total cases, there were 58 females
(59%) and 40 males (41%). There were 11 (12%) premature,
14% were 10 years of age, and 55% were >40 years of age.
There were 52 (53%) cases C. albicans and the remaining 47%Table 3 A comparison of clinical characteristics of candidemia p
Variable Survived (%)
Age, mean  SD 56.5  20.5
Sex, M:F ratio 23:33
LOS prior to candidemia 30  38.6
C. albicans 26/56 (46)
Complicated abdominal surgery 12/53 (23)
Presence of CVC 47/53 (89)
CVC removed 34/38 (89)
Total parenteral nutrition 27/49 (55)
Colonization with Candida 25/55 (45)
Prior antibiotic use 50/51 (98)
Prior antibiotic days 33  26
Prior antibiotic number 5  3.1
Neutropenia 5/54 (9)
Prematurity 7/54 (13)
Acute renal failure 8/52 (15)
Burns 10/56 (18)
Number of prior antibiotics 4  2.9
LOS, length of stay; CVC, central venous catheter. Denominators are the
available.were non-C. albicans (Table 1). The most frequent non-C.
albicans species were Candida tropicalis (19%) and Candida
parapsilosis (16%), Candida glabrata (7%), Candida krusei
(2%), Candida lusitaniae (1%), and Candida guilliermondii
(1%).
The predisposing factors for candidemia are shown in
Table 2. The majority of patients (62%) were in intensive
care units (ICU) when candidemia was detected. Of the total
patients, 23% were in the pediatric ICU, 10% in the coronary
care unit, 13% in the medical ICU, 11% in the neonatal ICU,
and 9% in the surgical ICU. In relation to predisposing factors,
83% of candidemia occurred in patients with central venous
catheters and 96% had received broad-spectrum antibiotics.
However, prior fluconazole use was low (8%). The average
number of antibiotics used prior to the development of
candidemia was 5  3.2 (range 1—18). On average, each
patient received 32  24 (range 2—111) days of antimicrobial
therapy prior to the infection. Other predisposing factors
included complicated abdominal surgeries (22%), TPN (52%),
neutropenia (9%), ARF (24%), burns (15%), malignancy (26%),
and prior colonization with Candida spp (48%). The range of
the length of hospital stay (LOS) prior to the development of
candidemia was 0—270 days with a mean  SD of 29.2  35.3
days. The initial treatment of patients with candidemia was
fluconazole in 60% and amphotericin B in 36%.
There were some significant differences between patients
with C. albicans and non-C. albicans candidemia. Patients
with non-C. albicans candidemia had had a higher number of
antibiotics (5  3.5 vs. 4  2.9, p = 0.006), more total days of
antibiotics (38  27.8 vs. 25  15.6, p < 0.001), and had had
a longer LOS prior to the development of candidemia
(33.4  33.4 vs. 25.4  36.9, p < 0.001). A comparison of
the differential characteristics of those patients with C.
albicans and non-C. albicans candidemia was done using a
logistic regression analysis. Patients with C. albicans candi-
demia were more likely to die (OR 5.31, 95% CI 1.41, 20.02,
p = 0.014) than those with non-C. albicans.atients who survived and who died
Died (%) p-value
51.8  29.2 <0.001
17:25
29  30.8 NS
26/42 (62) NS
8/38 (21) NS
27/36 (75) NS
20/22 (91) NS
19/34 (56) NS
19/36 (53) NS
34/36 (94) NS
29  21.7 <0.001
5  3.4 NS
3/38 (8) NS
4/37 (11) NS
13/36 (36) 0.014
5/42 (12) NS
5  3.5 0.006
number of patients for whom information on that characteristic was
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Figure 1 Comparison of Candida spp causing fungemia in
different studies from Saudi Arabia.
Table 4 Multivariate logistic regression model of mortality in 98 patients with candidemia
Variables studied Adjusted OR 95% CI Significance ( p)
C. albicans 5.91 1.50—23.24 0.01
Complicated abdominal surgery 0.38 0.07—1.99 0.25
Presence of CVC 0.34 0.07—1.73 0.19
Total parenteral nutrition 3.40 0.66—17.46 0.19
Colonization 1.70 0.45—6.36 0.43
Prior antibiotic use 0.001 0.00—7.53 0.747
Neutropenia 1.15 0.05—28.73 0.93
Prematurity 0.49 0.05—4.49 0.53
Acute renal failure 5.15 1.18—22.55 0.03
Burns 0.40 0.08—2.05 0.27
Prior antibiotic number 1.38 0.18—10.67 0.76
OR, odds ratio; CI, confidence interval; CVC, central venous catheter.The total crude mortality rate was 43% within 30 days of
developing candidemia. Nine patients died within 72 hours of
obtaining the blood cultures, the time by which positive
blood culture reports became available. The mortality rate
for C. albicans was 50%, non-C. albicans 34.8%, C. glabrata
43% (3/7), C. tropicalis 42% (8/19), and C. parapsilosis was
25% (4/16).
A comparison between patients who survived (n = 56) and
those who died within 30 days (n = 42) is shown in Table 3.
Patients who died were more likely to have had ARF (36% vs.
15.4%, p = 0.01) and had received a higher number of anti-
biotics (5  3.5 vs. 4  2.9, p = 0.006) than those who sur-
vived. However, using logistic regression analysis two
independent determinants of death were identified
(Table 4). These variables are the presence of C. albicans
(OR 5.91, 95% CI 1.50, 23.24, p = 0.01) and ARF (OR 5.15, 95%
CI 1.18, 22.55, p = 0.03).
Discussion
In this study, we evaluated the epidemiology and risk factors
for candidemia at a general hospital in Saudi Arabia. There
were a total of 98 distinct episodes of candidemia in the study
period from 1996 to 2004. There are no prior data from this
institution for comparison, however, and the total number of
episodes was low for the nine-year study period. The median
annual incidence of candidemia was 0.45 cases/1000 hospital
discharges. The annual mean of candidemia for Spain was
0.53 cases/1000 hospital discharges17 and 0.77/1000 dis-
charges in a study from the United Arab Emirates.18 The
median annual rate per patient-days in our hospital was 1.0
and was closer to the mean rate for Spain (0.73 cases/10 000
patient-days).17
Although the culture system employed (BACTEC) is an
adequate system for the detection of Candida, it is not
the highest yield system available. A second reason for low
incidence might be the types of patients seen in our institu-
tion. Although the hospital is an acute care hospital it does
not have patients with solid organ or bone marrow trans-
plants. Thus, on average the patients in our hospital are less
sick than in other hospitals. Other factors that might have
resulted in such a low incidence of candidemia include strict
adherence to sterile techniques during vascular line inser-
tion, short duration of intravascular devices, and short dura-
tion of antibacterial usage. However, the exact reason forsuch a low incidence could not be answered from the avail-
able data.
The prevalence of the different species of Candida in
blood stream infections varies from one institute to another.
The most frequent species causing fungemia in our study was
C. albicans and constituted 52% of all the isolates. In other
studies from Saudi Arabia, the predominance of C. albicans
from blood isolates has also been documented (Figure 1). The
rate of isolation of C. albicans has been 46%,15 50%,9,16 and
71%.14 In a study from a teaching hospital in the Eastern
province of Saudi Arabia, C. albicans fungemia constituted
only 19% of the total isolates.10 Similar to our findings, C.
albicans was the predominant species in some reports,6—
9,17,19,20 but is different from other reports that describe
the predominance of non-C. albicans.18,21,22
In the current study, the most frequent non-C. albicans
species were C. tropicalis (19%) and C. parapsilosis (16%).
The limited number of annual cases does not allow us to
evaluate temporal trends of frequency of the different Can-
dida species. In addition, the study did not account for C.
dubliniensis since this was not specifically identified in our
Candida species causing fungemia at a Saudi Arabian hospital 243laboratory. In previous studies from Saudi Arabia, the two
most common non-C. albicans species have been found to be
C. tropicalis and C. parapsilosis.9,14,15 In other studies, C.
tropicalis was found to be the most predominant non-C.
albicans species9,16 and C. parapsilosiswas themost frequent
species in one study.10 C. parapsilosis has shown an increasing
prevalence as a cause of fungemia in many centers around
the world.23 In the SENTRYprogram, C. glabratawas themost
common non-C. albicans species in the USA and its predomi-
nance was associated with the high rate of fluconazole use.23
In our study only 8% of the patients received fluconazole prior
to the development of fungemia. Thus, C. glabrata was
uncommon (6%) in our study.
The predisposing factors for the development of candi-
demia in our study were similar to those described pre-
viously.24 The majority of the patients had CVC (83%), TPN
(52%), and prior colonization with Candida spp (48%). Anti-
biotic use is a known predisposing factor for the development
of fungemia.10 This important risk factor was not assessed in
some studies from Saudi Arabia.16 In the current study,
antibiotics were used in 96% of patients with a mean of
5  3.2 antibiotics for a mean of 32  24.2 antibiotic-days
prior to the development of candidemia. In a study of pedia-
tric candidemia, 90.6% of patients were on antibiotic therapy
for 10.3  4.5 days.21 Candidemia-associated mortality has
been found to be 31—72%.10,25,26 Similarly, the crude mor-
tality rate in our study was 43% for all patients with candi-
demia, 50% for C. albicans and 34.8% for non-C. albicans. In a
study from Italy, the mortality rate due to candidemia was
14.2% and 40% in the C. albicans and non-C. albicans groups,
respectively.27 In another study, mortality associated with C.
albicans and C. parapsilosis was 39.5% and 11.1%, respec-
tively.28 The difference in the observed mortality rates
between these studies may be related to the severity of
the underlying diseases.
In conclusion, the study shows that the rate of candi-
demia was low in our hospital. C. albicans was the major
species causing fungemia followed by C. tropicalis and C.
parapsilosis. The crude mortality rate was 43% and two
independent determinants of death were the presence of
C. albicans and ARF. Unfortunately, in vitro susceptibility
testing for Candida spp is not done routinely at our hospital
and thus the lack of these data is one of the limitations of
the current study. Further studies are needed to determine
the change in the pattern of candidemia and to include
susceptibility testing.
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